Position of the Transparency Council – Albendazol Micro Labs
At its meeting on 14 April 2025, the Transparency Council adopted position No. 44/2025 on the justification for granting reimbursement for the medicinal product Albendazol Micro Labs for the following indications: hepatic echinococcosis caused by Echinococcus multilocularis; hepatic echinococcosis caused by Echinococcus granulosus